• Publications
  • Influence
MER-101-03, a multicenter, phase II study to compare MER-101 20mg tablets to intravenous zoledronic acid 4mg in prostate cancer patients.
Orazol weekly therapy appears to be as effective as Zometa, based on the biomarkers analyzed, and a rapid decrease for all four biomarkers was seen at seven days, and was sustained throughout the study.
MER-104 tablets: a dose-ranging study of an oral formulation of a gonadotropin-releasing hormone antagonist, acyline.
Therapeutically-effective levels of a decapeptide GnRH antagonist, acyline, can be achieved using an oral delivery platform, GIPET™, and indicate that MER-104 tablets may have potential in the treatment of prostate and breast cancer, endometriosis, prostate hypertrophy, and as part of a male contraceptive regimen.